Latest Conference Articles

Promising Combination Moves Into Kidney Cancer

Promising Combination Moves Into Kidney Cancer

June 7th 2017, 5:44pm

ASCO Annual Meeting

Bavencio and Inlyta together produced a promising response for some patients with renal cell carcinoma.

Drug Combination Is Effective in Urothelial Carcinoma

Drug Combination Is Effective in Urothelial Carcinoma

June 6th 2017, 10:06pm

ASCO Annual Meeting

When combined with the IDO1 inhibitor epacadostat, Keytruda (pembrolizumab), a PD-1 inhibitor, resulted in an overall response rate (ORR) of 35 percent in patients with advanced urothelial carcinoma, according to results from the phase 1/2 ECHO-202/KEYNOTE-037 trial.

Therapy Shows High Remission Rates in Multiple Myeloma

Therapy Shows High Remission Rates in Multiple Myeloma

June 6th 2017, 5:59pm

ASCO Annual Meeting

Many patients with relapsed or refractory multiple myeloma saw clinical remission with CAR T-cell therapy.

Will There Be an Immunotherapy Approval in Gastric Cancer?

Will There Be an Immunotherapy Approval in Gastric Cancer?

June 5th 2017, 9:55pm

ASCO Annual Meeting

Keytruda (pembrolizumab) showed promising signs of clinical activity for patients with advanced gastric or gastroesophageal junction (GEJ), according to updated findings from KEYNOTE-059 study that were presented at the 2017 American Society for Clinical Oncology (ASCO) Annual Meeting.

New Agent Shows Promise Across Many Cancers Which Have TRK Fusion Mutations

New Agent Shows Promise Across Many Cancers Which Have TRK Fusion Mutations

June 5th 2017, 6:48pm

ASCO Annual Meeting

Promising results from a new agent may set the stage for a new standard of care for patients with TRK fusion mutations.

With Patients Reporting Symptoms Using Web Tool, Survival Improves

With Patients Reporting Symptoms Using Web Tool, Survival Improves

June 4th 2017, 10:21pm

ASCO Annual Meeting

An online tool helped patients to report their symptoms in real time, improving survival, according to findings presented at ASCO 2017.

Patients With Low-Risk Colon Cancer Can Have Less Chemotherapy, Reducing Neuropathy

Patients With Low-Risk Colon Cancer Can Have Less Chemotherapy, Reducing Neuropathy

June 4th 2017, 10:06pm

ASCO Annual Meeting

According to findings presented at ASCO 2017, patients with low-risk advanced colon cancer would benefit from reducing the length of chemotherapy after surgery.

Staying CALM: Psychotherapy for Patients with Advanced Cancers

Staying CALM: Psychotherapy for Patients with Advanced Cancers

June 4th 2017, 8:19pm

ASCO Annual Meeting

The psychotherapty known as CALM has been shown to ease depression and distress in patients with advanced cancer.

Maintaining Mobility May Not Require More Than Single-Dose Radiation

Maintaining Mobility May Not Require More Than Single-Dose Radiation

June 4th 2017, 5:59pm

ASCO Annual Meeting

According to phase III findings presented at ASCO 2017, single radiation treatment relieved the symptoms of spinal cord compression in patients with advanced cancer as effectively as a five-day course.

Study Finds a Decline in Late Effects After Childhood Treatment

Study Finds a Decline in Late Effects After Childhood Treatment

June 3rd 2017, 8:38pm

ASCO Annual Meeting

There are fewer reported incidences of severe long-term side effects after childhood cancer treatment, according to a recent study.

Psychological Interventions Can Lower Fear of Recurrence

Psychological Interventions Can Lower Fear of Recurrence

June 2nd 2017, 11:47pm

ASCO Annual Meeting

A recent clinical trial showed that psychological intervention can ease patients' anxiety and fear of recurrence.

Combination Improves Breast Cancer Survival, Study Shows

Combination Improves Breast Cancer Survival, Study Shows

June 2nd 2017, 11:07pm

ASCO Annual Meeting

Progression-free survival was improved for postmenopausal women with HER2-negative advanced breast cancer when treated with Kisqali plus letrozole.

Lynparza Improves Progression-Free Survival in BRCA+ Ovarian Cancer

Lynparza Improves Progression-Free Survival in BRCA+ Ovarian Cancer

March 15th 2017, 9:19pm

SGO Annual Meeting on Women's Cancer

Patients with BRCA-mutant ovarian cancer saw an improved progression-free survival with Lynparza, according to a recent study.

Improving Survival in BRCA-Proficient Ovarian Cancer

Improving Survival in BRCA-Proficient Ovarian Cancer

March 15th 2017, 8:20pm

SGO Annual Meeting on Women's Cancer

Improved overall survival (OS) was achieved in patients with BRCA-proficient ovarian cancer who were treated with a carboplatin desensitization regimen.

Jubilee Brown on Genetic Counseling for Patients With Breast and Ovarian Cancer

Jubilee Brown on Genetic Counseling for Patients With Breast and Ovarian Cancer

March 15th 2017, 6:41pm

SGO Annual Meeting on Women's Cancer

Jubilee Brown, M.D., obstetrician-gynecologist, Levine Cancer Institute, Carolinas HealthCare System, discusses genetic counseling for patients with breast and ovarian cancer.

PARP Inhibitors Are Changing the Treatment Landscape for Ovarian Cancer

PARP Inhibitors Are Changing the Treatment Landscape for Ovarian Cancer

March 15th 2017, 4:52pm

SGO Annual Meeting on Women's Cancer

PARP inhibitors like niraparib are bringing big change to the treatment of ovarian cancer, says Kathleen N. Moore, M.D.

Kathleen N. Moore Discusses New PARP Inhibitors for Ovarian Cancer

Kathleen N. Moore Discusses New PARP Inhibitors for Ovarian Cancer

March 15th 2017, 12:37am

SGO Annual Meeting on Women's Cancer

Kathleen N. Moore, M.D., assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses developing new PARP inhibitors for patients with ovarian cancer. These new drugs may meaningfully prolong survival from a couple months to potentially years.

Niraparib Improves Progression-Free Survival in Ovarian Cancer, Regardless of BRCA Status

Niraparib Improves Progression-Free Survival in Ovarian Cancer, Regardless of BRCA Status

March 14th 2017, 10:32pm

SGO Annual Meeting on Women's Cancer

The PARP inhibitor niraparib proved to be effective in improving progression-free survival in recurrent ovarian cancer, according to a recent study.

Declining Concern about HPV Vaccine and Sexual Activity

Declining Concern about HPV Vaccine and Sexual Activity

March 13th 2017, 11:53pm

SGO Annual Meeting on Women's Cancer

Concern about vaccine safety and perceived lack of necessity remain the main reasons parents give for not having their teenage daughter vaccinated against HPV.

Genetic Counseling and Ovarian Cancer: 4 Questions With an Expert

Genetic Counseling and Ovarian Cancer: 4 Questions With an Expert

March 13th 2017, 10:26pm

SGO Annual Meeting on Women's Cancer

Jubilee Brown, M.D., answers some common questions about genetic counseling in patients with ovarian cancer.

Ursula Matulonis Explains the Use of PARP Inhibitors for Ovarian Cancer

Ursula Matulonis Explains the Use of PARP Inhibitors for Ovarian Cancer

March 13th 2017, 9:31pm

SGO Annual Meeting on Women's Cancer

Ursula Matulonis, M.D., professor of Medicine, Harvard Medical School, Medical Director of Gynecologic Oncology, Dana-Farber Cancer Institute, explains the benefits of PARP inhibitors for patients with ovarian cancer.

Rucaparib Shows Promising Activity in Recurrent Ovarian Cancer

Rucaparib Shows Promising Activity in Recurrent Ovarian Cancer

March 13th 2017, 8:59pm

SGO Annual Meeting on Women's Cancer

Elizabeth Swisher, M.D., discusses the ARIEL2 study, which proved that rucaparib may be a promising agent for patients with recurrent ovarian cancer.

Elizabeth Swisher Discusses Rucaparib's Side Effects for Patients With Ovarian Cancer

Elizabeth Swisher Discusses Rucaparib's Side Effects for Patients With Ovarian Cancer

March 13th 2017, 1:12am

SGO Annual Meeting on Women's Cancer

Elizabeth Swisher, M.D., professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses the side effects of rucaparib in the ARIEL2 trial, for patients with relapsed, platinum-sensitive high-grade ovarian carcinoma.